App-Quantinova.ai

CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia

Saad S Kenderian - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Gemtuzumab ozogamicin

Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Bone Marrow Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Largest Reported Experience with High Risk Hematologic Malignancies

Heather J. Symons - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Mycophenolate mofetil

Pre-Transplant Consolidation Chemotherapy for Acute Lymphocytic Leukemia (ALL) Does Not Impact Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Nelli Bejanyan - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Role of Hematopoietic Cell Transplantation Co-Morbidity Index (HCT-CI) in Selection of Conditioning Regimen for Patients Undergoing Allogeneic Hematopoetic Cell Transplantation (Allo-HCT) a Single Institutio

Jocelyn De Yao - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Mycophenolate mofetil

The Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Elderly Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in the Era of Tyrosine Kinase Inhibitor (TKI) : A Single Institute Experience

Noriko Doki - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

dasatinib

Ex Vivo T Cell Depleted HLA-Matched PBSCT with Post-Transplant Activated Donor-Derived NK Cell Infusions for High-Risk Acute Lymphoblastic Leukemia

Nirali N Shah - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Cyclophosphamide

Outcomes of Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Jane Olsen - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

Evaluation of Donor KIR2DL1 Allelic Polymorphism in the Setting of T-Cell Repleted Haploidentical Transplantation

Mariana Bastos-Oreiro - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

CD3/CD28 Co-Stimulated Activation of PI3K-mTORC2-AKT Metabolic Programming Augments Granzyme B Expression and Direct Cytotoxicity in Expanded Human iNKT Cells

Ramon I Klein-Geltink - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

cyclosporin A

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem Cell Transplant (ASCT)

Heather M. Hylton - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

Hepatitis B Immune Globulin Prophylaxis of Viral Reactivation during Stem Cell Transplant

Devona Williams - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Acute lymphoblastic leukemia

Hepatitis B Immune Globulin

Cytogenetics Does Not Influence Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia

Ibrahim Aldoss - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Tacrolimus

Outcomes of Patients with Acute Lymphoblastic Leukemia (ALL) with Central Nervous System (CNS) Involvement Undergoing Allogeneic Hematopoietic Cell Transplantation (AlloHCT): A Single Center Retrospective Analysis

Monzr M. Al Malki - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Allogeneic Hematopoietic Cell Transplantation (HCT) Yields Lower Relapse Rates but No Overall Survival Benefit for Adults with Acute Lymphoblastic Leukemia (ALL) in First Minimal Residual Disease (MRD)-Negative Remission

Ryan D. Cassaday - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

Racial disparity (RD) in cancer risk: Lessons from the global epidemiology of childhood acute lymphoblastic leukemia.

Christopher Kwesi Oladipupo Williams - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Pharmacokinetics/pharmacodynamics (PKPD) of blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).

Min Zhu - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Blinatumomab

Treatment-related hospitalization costs of pediatric acute lymphoblastic leukemia.

Anne C. Kirchhoff - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Clinical activity of ERY001 (erythrocyte encapsulated l-asparaginase) and native l-asparaginase (L-ASP) in combination with COOPRALL regimen in phase III randomized trial in patients with relapsed acute lymphoblastic leukemia (ALL).

Yves Bertrand - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Asparaginase

Clinical outcome of adult acute lymphoblastic leukemia based on Philadelphia chromosome status and socioeconomic status.

Bao Duy Dao - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Drug monitoring of ERY001 (erythrocyte encapsulated L-asparaginase) and native L-asparaginase (L-ASP) in combination with COOPRALL regimen in Phase 3 randomized trial in patients with relapsed acute lymphoblastic leukemia.

Yves Bertrand - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Asparaginase

Filters

2187 Abstracts